ABL Lyon, a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using single molecule measurement digital platform, Simoa. Quanterix, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, has selected ABL, the first CRO in Europe with the ability to develop new assays and validate methods for research or clinical testing to detect femtomolar levels of analytes in preclinical or clinical samples.
Rockville, MD, USA. ABL, Inc. (ABL), a biomedical contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the acquisition of a majority interest in Platine Pharma Services (Platine), a specialist in immunomonitoring and immunogenicity services. With laboratories located in Lyon, France, Platine helps clients in the biopharmaceutical, food, cosmetic and diagnostic industries evaluate the immunogenicity, activity and efficacy of products during R&D, preclinical and human clinical studies.
Our team will be happy to see you next month at Europe's largest meeting focued on cancer immunotherapy reasearch & development. A great opportunity to discuss your current and future needs in immunomonitoring! Don't hesitate to contact us at firstname.lastname@example.org should you want to shedule a meeting in advance.
The European Congress of Immunology took place recently in Glasgow, Scotland. It was the occasion for ABL's delegates to attend many high level Symposia and Workshops dedicated to the latest scientific breakthroughs in the field of Immunology, including recent findings in biomarker research, tumor immunology or advances in biologics.